摘要
分化型甲状腺癌(DTC)包括乳头状癌和滤泡状癌,占甲状腺恶性肿瘤的90%以上。DTC恶性程度不高,其肿瘤细胞保留了甲状腺细胞的摄碘功能,目前常用“手术+^(131)I治疗+甲状腺素抑制”的综合疗法治疗DTC,提高了DTC患者的生存率,但在DTC病变发展过程中,肿瘤细胞有失分化的趋势,其摄取碘的功能降低甚至消失。目前针对DTC治疗的研究趋势主要包括基因重组人促甲状腺激素的临床应用,维甲酸的诱导再分化及钠-碘转运体基因的研究。
More than 90% of primary thyroid cancers are differentiated papillery or follicular types. The popular treatment of differentiated thyroid carcinoma（DTC） consist of surgery, radioiodine ablation and thyroid stimulating hormone suppressive therapy, which increase clinical benefit rate. During tumor progression, cellular de-differentiation occurs in up to 30% of cases and usually result in the loss of iodine uptake. The current resercbes aiming to improve treatment effect of DTC including clinical application of rhTSH, retinoic acid inducement to re-differentiation and gene therapy on sodium-iodide symporter.
出处
《国际放射医学核医学杂志》
2006年第6期343-346,共4页
International Journal of Radiation Medicine and Nuclear Medicine
关键词
碘放射性同位素
甲状腺肿瘤
综合疗法
Iodine radioisotopes
Thyroid neoplasms
Combined modality therapy
